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Abstract
Jordana Baden.

Mapping the transcriptional start site(s) of the

cannabinoid receptor gene.

(Under the direction of Dr. Lisa Matsuda.)

The cannabinoid receptor gene has recently been cloned.
Comparisons of cDNA clones with genomic DNA show that the gene
consists of a coding region and at least two untranslated 5' exons (A
and B).

Two alternative transcripts, differing in their 5'

untranslated sequence, have been found that code for identical
receptors.

Primer extension for transcript A reveal that its most 5'

transcriptional start site corresponds to nucleotide -548.
Additional transcripts initiated 3' of -548 may exist.

Ribonuclease

protection assay and primer extension for transcript B reveal that
its most 5' transcriptional start site corresponds to nucleotide
-406.

It is possible that shorter transcripts, corresponding to

transcriptional start sites 3' of -406 may exist.

Background

Cell-surface

receptors

There are three ways to classify cell-surface receptors, as G
protein-coupled receptors, channel-linked receptors, or catalytic
receptors (1).
to specific ions.

Channel-linked receptors alter a cell's permeability
Upon binding of their ligand, the receptor's

conformation is changed to create an open tunnel which allows
specific ions to enter the cell.
IS

The signaling of th is type of receptor

extremely rapid and channel-linked receptors are mainly involved

in synaptic signaling between two electrically excitable cells (1).
Catalytic receptors can be described as membrane-bound
enzymes.

Ligand binding causes the cytoplasmic portion of the

receptor to exert a specific action within the cell.

To

date~

the

majority of catalytic receptors have cytoplasmic domains which
function as a tyrosine-specific protein kinase (1).

G protein-coupled receptors are the most complex class of
membrane bound receptors.

They can positively or negatively effect

a variety of channels or enzymes in the cell through their unique
second messenger system.

After a ligand binds to these receptors a
J

conformational change occurs which causes an increase in affinity
between the cytoplasmic domains of the receptor and a G protein.
The G protein is a heterotrimeric protein consisting of (from highest
molecular weight to lowest) Ga , G~ and Gy . Ga contains a binding

2
site for guanine nucleotides and has GTPase activity (2).

In their

basal state, the three subunits are bound to each other and GDP is
bound to Ga. Following the receptor's conformational change, the
receptor binds with the membrane bound G protein which causes the
G a subunit to release GDP, in exchange for GTP. The G protein then
disassociates from the receptor causing a decrease in the affinity
between the receptor and its ligand. The activated G protein can then
activate or inactivate membrane bound enzymes or channels.

These

enzymes can alter the concentration of specific molecules such as
calcium ions or cAMP which affect a variety of cellular responses.

Marijuana's

receptor-mediated

mechanisms

of

action

Marijuana has been used recreationally and therapeutically for
centuries.

However, it was not until thirty years ago that its

primary psychoactive compound, L\9-tetrahydrocannabinol (L\9- THC)
was isolated (Figure 1) (3).

Subsequent to the isolation of

L\~- THC

researchers focused on characterizing the effect of L\9- THC and its
metabolites (cannabinoids) on a variety of whole animal models.
Although these effects vary greatly depending upon the
concentration, the type of cannabinoid tested, and the animal model,
low doses tend to cause a mixture of depressant and stimulatory
effects whereas higher doses cause central depression (4,5).
The first evidence that the effects from lower concentrations
of cannabinoids might be the result of a receptor-based mechanism
came from an experiment which tested enantiomers of L\9- THC on
dogs (6).

L\9-THC exists in two forms that differ only by their chiral

centers at carbons 3 and 4.

By assessing the behavioral effects of
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Figure 1: Naturally occuring cannabinoid agonists. ~9-THC is numbered in
accordance with the dibenzopyran system.

4

the two enantiomers on dogs, Adams discovered that the effect of
~9-THC

were stereoselective (6).

The enantiomer with chiral

centers in the trans position, (-)d9-THC, was significantly more
potent in eliciting dog ataxia, a characteristic response to
cannabimimetic compounds.
For the next several years, researchers tried to
pharmacologically characterize the binding site of cannabinoids.
Through their structure-activity relationship studies, Binder and
Franke provided further evidence that a receptor existed for
cannabinoids (7).

They observed that very little change could be

made on the d9-THC molecule without causing complete loss of
psychotropic activity.

Several other studies also involved changing

moieties on cannabimimetic compounds and assessing their potency
to elicit a characterized response (See ref. 8 for review).

One such

study which assessed the analgesic potency of altered cannabinoids
reported that the important functional groups for eliciting Iqw
dosage effects were the phenolic A ring hydroxyl and the A ring alkyl
side chain (Figure 1) (9).
Binding studies involving natural cannabinoids were difficult
to perform due, in part, to physical characteristics of the classical
cannabinoids.

d9-THC and its metabolites tend to be lipophilic and

adhere to glass and plastic ware (10).

The elucidation of the binding

site for cannabinoids was made possible by the synthesis of several
cannabinoid analogs such as WIN 55,225, CP-55,940, and
levonantradol (11).

In 1988. Devane et al. characterized the

cannabinoid binding site using tritiated CP-55,940 in a
centrifugation assay (12).

This study demonstrated that a specific,
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saturable cannabinoid binding site existed in brain tissue (12).
Additionally, Devane et al. reported that ligand binding was
decreased by a nonhydrolyzable GTP analog (12).

This decrease in

binding affinity is characteristic of binding to a G protein-coupled
receptor.
Additional evidence that the cannabinoid receptor was a G
protein-coupled receptor was provided by other studies which used
synthetic cannabinoid analogs (9,13).

Howlett et al. reported that in

a neuroblastoma cell line, cannabinoids inhibit adenylyl cyclase (9,
13).

This inhibition of adenylyl cyclase appeared to be mediated

through a receptor coupled to a G protein since the inhibition
required GTP and was pertussis-toxin sensitive (9, 13).
The cannabinoid receptor, like other G protein-coupled
receptors, has seven transmembrane domains composed of
hydrophobic amino acids (1).
an extracellular N-terminus.

It has an intracellular C terminus and
Translation of the rat cannabinoid

receptor eDNA predicts that the receptor contains 473 amino acids
(14).

There are potential sites for N-linked glycosylation on

residues 78 and 84 (14).

From the amino acid sequence it is

predicted that the receptor would have a molecular mass of 52,844
daltons.

However, the actual molecular weight is most likely larger

due to the likelihood of glycosylation (14).
In addition to its negative coupling to adenylyl cyclase, the
cannabinoid receptor is known to couple also to potassium and
calcium channels.

The cannabinoid receptor has been shown to

decrease calcium conductance in the neuroblastoma x glioma hybrid
cell line, NG108-15 (15, 16).

Potassium channels are also positively

6

coupled to cannabinoid receptors In cultured hippocampal neurons
(17) .

Recently, an endogenous ligand for the cannabinoid receptor,
anandamide, an arachidonic acid derivative (Figure 1), was reported

by Devane et al. (18).

Their study tested the ability of porcine brain

fractions to displace a radio-labeled cannabinoid analog in a
centrifugation-based ligand binding assay.

Cloning and characterization of the cannabinoid receptor
gene

In 1990, the cannabinoid receptor gene was cloned in rats.

In

an attempt to find a novel G protein-coupled receptor, Matsuda et al.
(19) used a probe that was based on sequence encoding the second
membrane-spanning domain of the substance K receptor.

The choice

to use a probe based on this particular receptor was quite simple
owing to the fact that, at the time, this was the only neural peptide
receptor that had been cloned (15).

The second membrane spanning

domain is known to be quite conserved among many families of G
protein-coupled receptors.

The probe was hybridized to a rat

cerebral cortex cDNA library under low stringency conditions.

This

allowed binding of the probe to similar sequences that putatively
encoded a membrane spanning domain of a novel G protein-coupled
receptor.

This strategy detected a clone, SKR6, the sequence of

which was indicative of a G protein coupled-receptor.
Determination that SKR6 was a cannabinoid receptor clone
came through the fortuitous discovery that two cell lines known to
contain cannabinoid receptors expressed the SKR6 gene (19).

7
Furthermore, a cell line which was known not to contain cannabinoid
receptors did not express the SKR6 gene (19).

Additional evidence

that SKR6 coded for a cannabinoid receptor was provided when the
localization of SKR6 RNA and cannabinoid receptors in rat brain
were compared and observed to be similar (19).

Transfection of a

cell line which did not contain cannabinoid receptors with the SKR6
clone and subsequent exposure to cannabinoids resulted in an
inhibition of adenylyl cyclase (19).

This provided conclusive

evidence that the SKR6 clone coded for a cannabinoid receptor.
Soon after the cloning of the rat cannabinoid receptor, BS08, a
human cannabinoid receptor cDNA was reported (20).

The human and

rat cDNAs code for proteins with an amino acid identity of 97%, yet
their untranslated 5' regions were notably dissimilar.

To determine

if the variation in the 5' untranslated sequence was due to species
differences, rat and human genomic DNA was sequenced.

Both the 5'

untranslated 8808 sequence (herein referred to as exon 8) and the 5'
untranslated SKR6 sequence (herein referred to as exon A) were
found on human and rat genomic DNA (T.I. Bonner, unpublished data).
Exon B was upstream of exon A and the two were separated by
several kilobases (T.I. Bonner, unpublished data).

Sequencing of

genomic DNA also revealed that the coding exon of the cannabinoid
receptor gene contains 63 bp of 5' untranslated sequence, the protein
coding region, and 3.7 kilobases of untranslated sequence (T.I.
Bonner, unpublished data).

Using this data, a model of the

cannabinoid receptor gene can be constructed (Figure 2).
The alternative 5' regions of the rat and human clones are not
due to species differences (T.1. Bonner, unpublished data) but are the
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Figure 2: A model of the rat cannabinoid receptor gene (not drawn to scale).
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result of alternative 5' exons.

Thus, at least two transcripts that

encode for the same cannabinoid receptor exist.

By studying the

different sequences of the transcripts, certain characteristics can
be examined such as the half lives of the transcripts or whether the
RNA (and consequently the protein) is preferentially localized within
the cell.

Moreover, the rate at which the transcripts are translated

can be quantitated.

Important aspects regarding the regulation of a

gene's expression can also be ascertained by analyzing upstream
genomic sequence. Gene expression may be induced or repressed in a
time-dependent manner.

Similarly, it is possible that the gene is

preferentially expressed in certain tissues.

In order to investigate

these issues, two factors must first be determined: the start site of
each of the transcripts and the sequence differences in the
transcripts.

The objective of this project is to determine the

sequences and start sites of the alternative transcripts encoding the
cannabinoid receptor.
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Strategy and

Experimental

Procedures

The original strategy used to map the transcriptional start
site was to generate transcripts encompassing the entire 5' end of
the cannabinoid receptor gene using RACE (Rapid Amplification of
cDNA Ends) (21, 22), and then subclone and sequence the transcripts.
Ribonuclease protection assays and primer extensions would then be
used to confirm the results.
RACE was first described by M. Frohman (21) in order to
provide information on the 5' or 3' end of cDNA.

RACE is similar to

the more traditional primer extension mapping method in that a
cDNA is synthesized or "extended" from an RNA template by reverse
transcriptase and a primer specific for the gene.

Unlike primer

extension, RACE amplifies the cDNA by PCR through a series of
denaturing, annealing and extension steps.

Two sets of primers are

used in the amplification, gene specific primers (GSP-1 and GSP-2),
and RACE primers (Ri, Ro, Ri/Ro-TTTT).

These primers are nested

such that the two rounds of amplification not only increase the yield
of eDNA but increase its specificity as well.

A diagram of RACE is

shown in figure 3.
A second strategy to generate RACE products is described by
Edwards et al. (22).

This strategy (herein referred to as RACE-2)

differs from Frohman's original RACE strategy (herein referred to as
RACE-1) in the method employed to supply necessary, known
sequence on the 3' end of the reverse transcribed cDNA; RACE-1
achieves this by using terminal dideoxytransferase (TOT) to add a
poly-A tail and RACE-2 employs T4 RNA ligase to attach an
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initial template to amplify the leader sequences of both 5' exons.
Additionally, a second cDNA pool was synthesized using random
hexamers.

This has been shown to increase the probability of

producing a cDNA from a relatively rare RNA (24).

The cDNA to be

used for RACE-1 was treated with RNAse H to degrade the RNA
hybridized to the first strand cDNA, poly-A tailed, and purified uSing
the Spin-Bind Purification system (FMC).

For RACE-2, the RNA was

hydrolyzed with NaOH and the cDNA was cleaned with the "GenoBind" system (Clontech).

The anchor was then ligated to the RACE-2

cDNA.

Amplification

of

cDNA

Using the OLIGO 4.0 program for Macintosh and putative
sequence from exon A and exon B (T.1. Bonner, unpublished), gene
specific primers were selected.

Primers for RACE-1 were chosen

that had a similar melting temperature to that of Ro-RiTTT, Ro, or
Ri.

Primers for RACE-2 were chosen that had a similar melting

temperature to that of the anchor primer.

All primers were analyzed

to ensure that they would not form stable hairpins or stable dimers
with the other primers (Figure 5 and Table 1).
cDNA was amplified in a 50 J.l1 reaction.
contained 1X peR buffer, 25

~M

Taq DNA Polymerase (Gibeo).

For RACE-1 10 ].11 of

The basic reaction mixture

primers, 0.2 mM dNTPs, and 2.5 units
First round amplification products

were diluted 1 :20 and were used as template for the second
amplification cycle.

Anchor-ligated cDNA to be used for RACE-2

was amplified in the same manner with the exception of a lower
concentration of primers (10 f.lM).

Only one round of amplification

Exon A

Coding Exon

5'

3'

-548

17mer sense

-64

l-------------------~I

I

-63

-1

I
GSP1-A

----39mer A
-17mer a.sense

--GSP2-A

Coding Exon
Exon B

5'

~enseB2

-406

---SenseB1
-64

3'
-63

-1

39mer B
-GSP4-B

-GSP2-B

-GSP1-B

--GSP3-B
key

r----

= introns
=exons
50 bp

Figure 5: Location and size of primers and probes. Numbers refer to base pairs with -1 designating the most 3'
base of the untranslated leader sequence.
J

-.L.

(Jl

Primer

Sequence (5'-->3')

%GC

SKR62 1 ,2
GSP1-A3,4
GSP2-A3,4
s.17merAS
as.17mer AS
39mer A5,6
GSP1-B3,4
GSP2-B3,4
GSP3-B3,4
GSP4-B3,4
SenseB1 2
Sense B22
39mer 8 5 ,6

TTCAGCTAGGATCTACCGGAACGTCTGTGGTGGAAGGCATGGTAGTGG
TGGCGTCCTCTGTTGA
CCAGCCACAGCAACT
TTTCTGATTACGTCCAC
AAAATATTTCTCTCAGT
AACTGAGTTAGAGAAGGTGGGGTAGGGAGGGGAAGGGAG
GTCCACGGCCCAGAA
TTICCCCCCAGAACTC
GCTGGCTCTCTGCTAC
GCCAGGGGAGCCAGAA
CCAGCCCCTTGGCTGGGCGACAGGTGCC
TCCCCTGGCTCAGGCGGGAGCCTGGGCTGT
GGAAAAGAAGTGGAGAAGGTAGAGGCAGAGAGCGAGCAG
ATGTCGACCTCGAGACT
AGGATCCATCGATGTCG
AAGGATCCATCGATGTCGACCTCGAGACTGACT(17)
TCTGAAGGTTCCAGAATCGATAG

54.2
56.2
60.0
41.2
23.5
56.4
66.7
56.2
62.5

Ri 3
Re 3

Ri/RoTTTT3
Ancher 4

1
2
3
4
5
6

68.8
74.1
73.3

53.8
52.9
52.9
34.7
56.5

Used for reverse transcription of cDNA
Used for PCR
Used for RACE-1
Used for RACE-2
Used for sequencing
Used for primer extension

Table 1: Sequence and

GC

content of primers and probes
--&.

0">
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was performed in RACE-2.
electrophoresis on a 4%

Products were analyzed by

polyacrylamide gel.

The gels were stained

with ethidium bromide and photographed.

Subcloning RACE products
Amplification products were treated with Klenow and cut with
a restriction enzyme (Xho I) the recognition site for which was
included in the sequence of the Ri primer.

The plasmid, Bluescript II

SK (pBS), was cut with Sma I and Xho I, combined with the RACE
products, and the DNA ligated overnight.

Competent E. coli (XL-1

blue) were transformed and colonies containing the desired plasmid
were identified by Southern blot analysis of miniprep DNA (25).
Miniprep DNA was cut with Xho I or BamHI to linearize the plasmid
and Xho

1

and BamHI to isolate the insert. The DNA was

electrophoresed on a 1 .2%

agarose gel.

Southern blots were prepared

from the gels as described by Maniatis et al. (26).

Blots were

prehybridized for 2 hours (60 0 C, 6X SSG and 5X Denhardt's),
hybridized for 3 hours (60 0 G, 6X SSC, 3X Denhardt's, 500,000
DPM/ml of a 32p labeled 39mer oligonucleotide probe [Figure 5 and
Table 1]) and washed (4 X 20 minutes, 60 0 C, IX SSC). Blots were
exposed to film with enhancing screens (24-72 hours).

Additional

DNA from clones that hybridized with the probes were obtained by
cesium chloride density gradient plasmid isolation.

Sequencing

plasmids

The subcloned DNA was sequenced by the chain-termination
method of Sanger et al. (27) using the Sequenase Version 2.0 system
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(USB).

Plasmids were denatured with alkali, precipitated and then

annealed with primers specific for pBS.

The primers were extended

with the Sequenase Polymerase, deoxynucleoside triphosphates~ and
35S dATP.

The addition of dideoxynucleoside triphosphates

terminates the extension reactions.
analyzed on 6-8%

Sequencing reactions were

polyacrylamide, 7M urea denaturing gel.

The gel

was fixed (15 minutes) in 10% methanol, 10% acetic acid, dried (30
minutes) and exposed to film (3-7 days).

Verification of Start Site Identified by RACE:
Primer

Extension

Primers specific for exon A (39mer A) or exon B (39mer B)
(Figure 5 and Table 1) were chosen which begin approximately 100
base pairs 3' of the putative transcriptional start sites of their
respective exons.

Total cerebellar RNA (12.5 I1g) was denatured

(65 0 C, 5 minutes) and a reaction mixture containing AMV-RT, 1X
reverse transcription buffer, 12.5 11M primer, 0.2 mM dATP, 0.2 mM
dGTP, 0.2 mM dTTP, .02 mM dCTP and 65 J-lCi 32p-dCTP was added.
The reaction mixture was incubated (42 0 C, one hour) and passed
through a G50 column. The labeled cDNA (100,000 DPM) was
denatured and electrophoresed on a 8%

.

polyacrylamide 7M urea gel.

Sequencing reactions of genomic DNA primed with 39mer A or 39mer
B were electrophoresed next to either the exon A or exon B primer
extension product, respectively.

The gel was fixed (15 minutes) in

10 % methanol, 100/0 acetic acid, dried (30 minutes) and exposed to
film with enhancing screens (1-7 days).
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Ribonuclease

Protection

Assay

Genomic DNA flanking the sequence from both exons is
available (T.I. Bonner, unpublished data) and it is from this genomic
DNA that the probes for the protection assay were derived.

A

genomic DNA fragment (Sau96 I/Hinc II) was inserted into pBS at the
Eco RV and Hinc II sites.

The Hinc II site of this genomic fragment

is located 68 bp upstream from the 3' end of exon A, and the Sau 96 I
site is 320 bp further upstream (T.I. Bonner, unpublished data).

The

resultant plasmid, pSL, was used to generate the probes for
protection assay of transcript A.
EcoRI.

pSL (2).1g) was cut with Xho I or

The antisense probe was transcribed from the Eco RI cut

plasmid using T7 RNA polymerase. To generate the sense probe, the
Xho I treated plasmid was transcribed with T3 RNA polymerase.
Plasmids pAS and pA6 were used to determine the transcriptional
start site of exon B.

pA5 contains genomic sequence (Msc IIEeo NI)

which resides in pBS between the Hinc II and Xho I sites. The Eco NI
site is found 69 bases upstream of the 3' end of exon B and the Mse
site is approximately 800 bases further upstream (T.I. Bonner,
unpublished data).

Three hundred bases (Bst XI/Sty I) were removed

from the 5' end of the pAS insert to yield pA6.

The antisense probe

for exon B was generated from pAS (2).1g) cut with Pie I and
transcribed with T7 RNA polymerase.

The sense probe was

transcribed from 2).1g of pA6 cut with Xho I and transcribed with T3
RNA polymerase.

Transcription of the plasmids was done in the

presence of 30 ).1ei 32P-UTP,

The reaction was treated with DNAse

and probes were electrophoresed on a 40/0 polyacrylamide, 7M urea
gel.

The probes were cut from the gel after visualization on a film
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autoradiograph.

The probes were eluted overnight (37 0 C) in 500 ~I

0.5 M ammonium acetate, 1mM EOTA, 0.1 % 80S. The labeled probe
(100,000 - 300,000 DPM) was then hybridized to 45 - 100 J.l9 of

either cerebellar RNA or tRNA (85 0 C, 10 minutes; 50 0 C, overnight).
The hybridization reaction was then treated with RNAse T1 and
RNAse A and incubated (37 0 C, 30 minutes). The RNases were
inactivated by mixing the reaction with an equal volume of 4M GnTC/
0.1 M ~-mercaptoethanol.

isopropanol.

The reaction was then precipitated with

The pellet was resuspended in 5 J-li formamide loading

buffer and denatured.

The reactions were electrophoresed on a 4%

polyacrylamide, 7M urea gel.
methanol, 10 %

The gel was fixed (15 minutes) in 10 %

acetic acid, dried (30 minutes) and exposed to film

with enhancing screens (7-10 days).

peR analysis transcript B
Ribonuclease protection assay for exon A could not distinguish
a transcript whose leader sequence contains sequence exclusively
from exon A from a transcript which contains sequences from both
exon A and exon 8 due to splicing.

In order to insure that no such

transcript exists, PCR analysis using an antisense primer from the
5' end of the coding region (SKR62) with sense primers specific for
exon B sequence (S82 [Figure 4 and Table 1]) was carried out on
brain-derived cDNAs.

The thermocycling conditions were: 100 0 C

(45 seconds), 75 0 C (45 seconds), 72 0

C (1 minute) repeated for 35

cycles followed by a final extension period (72 0 C, 7 minutes).
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Resu Its

The A RACE-1 product was about 300 base pairs.

Subcloning of

A RACE-1 products was attempted several times and miniprep DNA
from numerous transfected colonies were analyzed by Southern
blotting to ascertain that the correct RACE product was present.

Of

the dozens of putative A clones analyzed only 3 hybridized to the
exon A specific probe (39mer A).
The three A clones were sequenced (both strands) and one of
the clones corresponded to known genomic sequence.

From this

clone we ascertained that the transcriptional start site of exon A
-472.

IS

These data suggest that exon A is 409 bp.
Primer extension analysis of cerebellar RNA primed with

39mer A, however, did not confirm the data provided by the A RACE1 product.

The 39mer A primer begins at nucleotide -378.

Thus, if

exon A begins at -472, a 94 bp extension product would be present.
As seen in Figure 6, a primer extension product was detected at 170
bp.

This corresponds to a start site of -548.

Additional primer

extension products corresponding to transcriptional start sites of
-547 and -545 could also be detected (data not shown).

It is not

known why the A RACE-1 product was truncated at its 5' end,
however, since a primer extension product of 94 bp was not detected
the transcriptional start site of -472 is most likely incorrect.
Protection assay of exon A was unsuccessful.

This may be explained

by the fact that the expression of transcript A is notably low in
brain tissue (L.A. Matsuda, unpublished results).

From these data,

22

Sequencing
reaction

/""-.
70bp

100 P .

Figure 6: Autoradiograph of primer extension for transcript A primed
with 39merA. Sequencing reaction lanes are A, C, G, T.
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AACTAGGAGTAGCCGACCTCCGAGGTCCCCACAGGACTGTCTGATTTAAAG
-548 --------------------------------------------------- -498
TTGATCCTCATCGGCTGGAGGCTCCAGGGGTGTCCTGACAGACTAAATTTC
TGCTGGTCTTCTAATCCCAGCTTTTGACAATTTGAAAGGGAGATAGATCTA
-497 --------------------------------------------------- -447
ACGACCAGAAGATTAGGGTCGAAAACTGTTAAACTTTCCCTCTATCTAGAT
CTGATCGATTTTTCTCTGTCCCCTCCTCCCTCCCTTGCCCCTCCCTACCCC
-446 --------------------------------------------------- -396
GACTAGCTAAAAAGAGACAGGGGAGGAGGGAGGGAACGGGGAGGGATGGGG
ACCTTCTCTAGCTCAGTTAGGAGCAATTCTATCAAAATGAAAGGCCGCGAA
-395 --------------------------------------------------- -345
TGGAAGAGATCGAGTCAATCCTCGTTAAGATAGTTTTACTTTCCGGCGCTT
TACTTTCTTAACTGAGAGAAATATTTTTTTCTGATTACGTCCACAGAGGAA
-344 --------------------------------------------------- -294
ATGAAAGAATTGACTCTCTTTATAAAAAAAGACTAATGCAGGTGTCTCCTT
CAGAATGCGTGCACCTCTAGCATGCTAAGCAGCACACACTGCAGGCTGTTG
-293 --------------------------------------------------- -243
GTCTTACGCACGTGGAGATCGTACGATTCGTCGTGTGTGACGTCCGACAAC
GTTTAGGCACACGAGCAGTTGCTGTGGCTGGGAAAGAGGCTTCATGTTGAC
-242 --------------------------------------------------- -192
CAAATCCGTGTGCTCGTCAACGACCCCGACCCTTTCTCCGAAGTACAACTG
ATGGTTTAAAAAAAGAAAAAAGRAAAAACCTAATCATTTTAGGKCGTTAGG
-191 --------------------------------------------------- -141
TACCAAATTTTTTTCTTTTTTCYTTTTTGGATTAGTAAAATCCMGCAATCC
AGAACTTACTGTGAACAGGCYCYTTTATTTCTTCAAAAGATGTCTCCCATT
-140 --------------------------------------------------- -90
TCTTGAATGACACTTGTCCTRGRAAATAAAGAAGTTTTCTACAGAGGGTAA
TCAAGCAAGGAGCACCCATGGCTGAG
-89 --------------------------AGTTCGTTCCTCGTGGGTACCGACTC

-64

Table 2: Sequence of exon A. Sequence obtained from RACE product
includes nucleotides -472 to -212. Additional sequence obtained
from genomic DNA sequences (T.1. Bonner, unpublished data).
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the most 5' transcriptional start site of exon A is -548 and its
length is 485 bp (Figure 9).

The full sequence of exon A is shown In

Table 2.
RACE of transcript B did not yield interpretable data.
Northern analysis data revealed transcript B was approximately 6 kb
(L.A. Matsuda, unpublished data), therefore exon B was less then 1 kb.
Previous protection probes (pA 1-pA4) showed complete protection
of the genomic fragment.

Therefore, pA5 was the probe which

contained the putative initiation site with additional 5' flanking
sequence. The probe used for protection assay of transcript B
contains 52 bp of vector sequence and 273 bp of genomic DNA
sequence beginning at nucleotide -467.

Ribonuclease protection

assay of exon B revealed protected fragments of 207 bp, 164 bp, and
157 bp (Figure 7).

These bands correspond to start sites of -406,

-363, and -356 respectively.

In Figure 7 a band corresponding to

285 bp can be detected in lane 2.

This band is not a true protected

fragment as it is less than 52 bp shorter than the probe.

No RNase

protection of the sense-strand probe was observed (data not shown).
Primer extension analysis for transcript B was primed with 39mer
B.

This primer begins at nucleotide -245.

Extension products of 161

bp, 160 bp, and 155 bp are clearly detected (Figure 8).

These bands

correspond to transcriptional start sites of -406, -405, and -400.
Additionally, shorter products can be seen throughout the lane.
may be due to incomplete reverse transcription.

This

Two of the shorter

bands, 118 and 111, are noted as they correspond to the
transcriptional start sites of -363 and -356 detected by protectio n
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Sequencing
reaction

/\
300b

probe
(325 bp)

207bp
200 b

164bp
157 bp

-Figure 7: Autoradiograph of RNase protection assay of exon B.
Sequencing reaction lanes are A, C, G, T. Lane 1: 25 J..lg cerebellar
RNA/75 J..l9 tRNA, Lane 2: 50 J..lg cerebellar RNA/50 J..lg tRNA , Lane 3 :
100 J..l9 cerebellar RNA, Lane 4: 100 J..l9 tRNA
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Sequencing
reaction

/'..
200bp

161 bp
;'~160bp

'155 bp

100 bp-

~ ~118

bp

~111

bp

.

Figure' 8: Autoradiograph of primer extension for transcript B primed with
39mer B. Sequencing reaction lanes are A, C, G, T.
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GGGCTGTGGCGCACGGGTGCTAGAGGCCAGGGAXGCGGGCGCGCAGACCGA
-406 --------------------------------------------------- -356
CCCGACACCGCGTGCCCACGATCTCCGGTCCCTYCGCCCGCGCGTCTGGCT
CTGACTTACTGACCGATCGCCGCGGGCACGCCCCGCTCCACCCCGCCCCGC
-355 --------------------------------------------------- -305
GACTGAATGACTGGCTAGCGGCGCCCGTGCGGGGCGAGGTGGGGCGGGGCG
CGCGCCCCGCGCCGCCTCCCCTGCTCGCTCTCTGCCTCTACCTTCTCCACT
-304 --------------------------------------------------- -254
GCGCGGGGCGCGGCGGAGGGGACGAGCGAGAGACGGAGATGGAAGAGGTGA
TCTTTTCCGCCTCCGCCTCCTTCTGGCTCCCCTGGCGCCAGAGCCTTCCCC
-253 --------------------------------------------------- -203
AGAAAAGGCGGAGGCGGAGGAAGACCGAGGGGACCGCGGTCTCGGAAGGGG
TGGCTCAGGCGGGAGCCTGGGCTGTCTGCAGAGCTCTCGTAGAGTCTGGGGG
-202 --------------------------------------------------- -152
ACCGAGTCCGCCCTCGGACCCGACAGACGTCTCGAGAGCATCTCAGACCCC
GXAAATTTCCTTGTAGCAGAGAGCCAGCCCCTTGGCTGGGCGACAGGTGCC
-151 --------------------------------------------------- -101
CYTTTAAAGGAACATCGTCTCTCGGTCGGGGAACCGACCCGCTGTCCACGG
GAGGGAGCTTCTGGGCCGTGGACCGGGGGATGAGAAG
-100 ------------------------------------CTCCCTCGAAGACCCGGCACCTGGCCCCCTACTCTTC

-64

Table 3: Sequence of exon B. Sequence obtained from genomic DNA
sequences (T.1. Bonner, unpublished). The 27 bp GC rich region is in
bold type.
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5'

3'

exon B

exon A

--i485 b~

1343 bg

coding exon
coding

163 bPi

regico

3.7 kb

~

- - exon A - - - - - - - coding exon - - - - - - - - transcript A

485 bp
-548

coding

163 bPi

regico

3.7 kb

1

- - exon B - - - - - - - coding exon - - - - - - - - coding

343 bp

transcri pt B

-406 * *

reg1co

3.7 kb

1

Figure 9: Summary of data. Top drawing: A model of the rat cannabinod receptor
gene. Middle drawing: A model of transcript A (1 denotes first base of translated
sequence). Bottom drawing: A model of transcript B. *s denotes possible initiation
sites corresponding to nucleotides -363 and -356.
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assay.

From these data, it appears that the most 5' transcriptional

start site of exon B corresponds to -406.
is 343 bp.

The full length of exon B

The full sequence of exon B is shown in Table 3. A

summary of these data is shown in Figure 9.
Amplification of B RACE products was a challenging process.
The three times B-RACE yielded products were they were seen as
multiple bands ranging from 300 - 500 base pairs.

This difficulty In

amplification of exon B may be explained by a 27 nucleotide stretch
which contains only guanidine (G) and cystidine (C) residues (Table
3). This segment has a T m of 97.5 0 C and a stable 11 base pair
hairpin.

These 27 bp are also flanked by DNA stretches with a

notably high (>400/0) GC content.
are often difficult to amplify.

Sequences that are extremely stable

Deep vent polymerase (NEB), a high

temperature polymerase, was tested to allow the denaturing
temperature to be raised to 100 0 C.

Testing of the high temperature

polymerases and a variety of primers on various cDNAs yielded no
products greater than 100 bp.
The multiple B RACE-1 products were subcloned and mlnlprep
DNA from transfected colonies were analyzed by Southern blotting.
None of the potential B clones hybridized with the exon B specific
probe (39mer B).
One of the reasons subcloning may have proved so difficult for
both A and B RACE-1 products was the subcloning strategy.

The

"adapter primer" used for RACE-1 contains an Xho I site which was
used to select for the insert.

The Xho I site is 3 bases away from

the end and it is known that Xho I cuts only at 10 %
two hours if its recognition site is near the end.

efficiency after

In order to
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ameliorate this potential problem, the incubation time for the Xho
cut was increased from 1 hour to overnight.

Originally, pBS was not

phosphatase treated and the vector and small insert may have
recombined during the ligation step.
Subcloning RACE-2 products would not prove as difficult since
the anchor contains an Eco RI site for post-amplification cloning.
This enzyme restricts DNA at >900/0 efficiency within 2 hours when
its recognition is flanked by only a minimum of additional sequence
(NEB, product literature).

This potentially easier subcloning

strategy was one of the reasons RACE-2 was attempted.

Another

advantage of RACE-2 is that a homogenous population of cDNA should
be produced.

Unlike the ligation step employed in RACE-2 to supply

known sequence to the 3' end of the cDNA, the tailing of the cDNA
employed by RACE-1 potentially generates cDNAs of various lengths.
Unfortunately, RACE-2 did not generate any product for either of the
transcripts.

Single-stranded ligation often proves difficult and

most likely was the problem in obtaining results (communication
with Clontech).
PCR analysis for the B transcript produced an amplification
product of a single band of the expected 258 bp (Figure 10).

If

transcripts exist that contain exon A sequences between those of
exon B and the coding region, additional peR products would be
expected to be present.

These data suggest that transcripts

containing sequences from both exon A and exon B do not exist for
the cannabinoid receptor.
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300bp
200bp

Figure 10: Photograph of peR analysis of exon B. Lane 1 : Standard reaction
mixture, Lane 2: Reaction mixture lacking primer SKR62, Lane 3: Reaction
mixture lacking cDNA, Lane 4: Reaction mixture lacking primer SB2.
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Discussion

Assuming there are no 5' exons other than exon A and exon B, it
IS

logical to assume that the two transcripts of the cannabinoid

receptor gene have separate promoters directing their transcription.
Alternative promoters provide flexibility in the expression of a gene
(29).

In addition to the possible differences in their expression, the

transcripts may have inherent differences in their stability,
translational efficiency and/or subcellular localization.
Promoters are defined as the sequence of DNA to which the
RNA polymerase binds (1).

Several transcription factors are known

to interact with the RNA polymerase to initiate transcription (1).
Transcription factors can be tissue specific and/or specific for a
particular developmental stage.

It is possible that possession of

alternative promoters allows the cannabinoid receptor gene to be
expressed in a tissue- or developmental stage-specific manner (29).
The RNA for the cannabinoid receptor has been found to be
expressed in a variety of tissues (15).

Northern analysis has

demonstrated that cannabinoid receptor RNA is expressed in brain,
lung and testis.

peR-based analysis detects expression in spleen,

thymus and some blood cells.

Additionally, expression of the

cannabinoid receptor gene has been found in several cell lines
including neural cell lines, lung fibroblasts and immune cells.

These

studies have not addressed whether transcript A or B is produced, so
further studies are necessary to ascertain if either transcript is
expressed in a tissue-specific manner.
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Several studies have examined the temporal dynamics of the
cannabinoid receptor.

Using in situ hybridization histochemistry the

RNA for the cannabinoid receptor has been detected in the embryo as
early as day 12 in rat brain (30).

A study done by Mailleux and

Vanderhaeghen observed that cannabinoid receptor mRNA decreases
by 50%

in aged rats (31).

Whether one transcript is preferentially

expressed during specific developmental stages, has yet to be
studied.
Analysis of rat brain RNA provides evidence that the two
transcripts are not produced in equal amounts (L.A. Matsuda,
unpublished data). In situ hybridization histochemistry with probes
specific for the untranslated 5' portions (leader sequence) of
transcripts A or B leader sequence has shown that, in rat brain,
mRNA with the B leader sequence is more abundant than mRNA
containing the A leader sequence. This may be due to exon 8's
promoter being stronger than exon A's promoter.

The transcript for

the amylase gene, Amy1, has been shown to have multiple promoters,
with the upstream promoter being stronger (32).

In mouse and rat,

the transcription of more than 100 times the amount of amylase RNA
initiates from the upstream promoter (32).

Expression of the c-myc

gene also results from alternative promoters.

In contrast, however,

the difference in transcript concentrations may result from the
stability conferred by the alternative leader sequences (33).

Thus,

it is possible that in the rat brain, cannabinoid receptor transcripts
are produced in equal amounts but that they differ in their relative
stabi I ities.
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The half-life of mRNAs vary greatly; certain mRNAs are
degraded in 20 minutes while other mRNAs have half lives of over 24
hours (34).

Since a single mRNA can be translated numerous times,

ascertaining its half-life can give information regarding
transcriptional stability.

It is believed that mRNAs are not degraded

until their poly-A tails are shortened to less than 10 nucleotides, a
length that is incapable of binding to the poly-A binding protein with
Once the tail is shortened, mRNAs may be more

high affinity (35).

susceptible to endonuclease attack and subsequent degradation.

In

this case, therefore, the rate at which RNA is degraded is controlled
by the removal of the poly-A tail and the 5' sequence of two
alternative transcripts, would not necessarily affect the
deadenylation step (35).

There is evidence, however, that a

transcript must be translated before it is degraded (35).

In this

situation, the transcriptional stability would be inversely
proportional to the translational efficiency of the message.
Four features have been shown to effect translational
efficiency (36).

First, the presence of a methylated cap structure

which is readily accessible seems to be a universal constant for
eukaryotic mRNAs.

The remaining three factors are a lack of

secondary structure in the 5' leader sequence, the absence of AUG
cedens upstream of the initiating AUG, and the length of the leader
sequence.

These factors are all directly related to the 5' leader

sequence of an RNA molecule.
The rate limiting step in translation is usually initiation (37).
During initiation, the RNA comes in contact with the translational
machinery.

A long (> 100 nucleotides), unstructured leader sequence
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has been shown to increase the rate of the translation (36).
Initiation is thought to occur from the polyribosomes in concert
with their cofactors, scanning the RNA for the first AUG codon.

If

the leader sequence contains excessive secondary structure the
scanning process may be hindered.
Secondary structure in the 5' leader is most often the cause of
inefficient translation in eukaryotic mRNAs (36).

Indeed the

majority of eukaryotic mRNAs lack secondary structure in their 5'
leader (38).
Based on our data, it could be argued that transcript A would
have a higher translational efficiency than transcript B.

The

presence of the GC rich region in the 5' untranslated sequence of
transcript B could potentially form secondary structure which could
hinder translation (36).

Moreover, the 5' untranslated sequence of

transcript A is longer than that of exon B.

Having a long 5'

untranslated sequence relatively free of secondary structure has
been shown to enhance translational efficiency (36).

Consequently,

the higher translational efficiency of the A transcript could cause it
to be degraded more quickly than the B transcript (35).

This idea is

consistent with the relatively high concentration of the B transcript
compared to the A transcript that is found in rat brain (L.A. Matsuda,
unpublished data).
Until fairly recently it was assumed that the localization of
proteins was due to signaling sequences on the nascent peptide. A
protein's ultimate destination was believed to have no relationship
to where the mRNA itself was translated.

In 1987, evidence was

provided that, in neurons, the mRNA, itself, may influence the
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protein's final location.

In a study tracking tritiated RNA through

cultured hippocampal neurons, Davis et al. found that RNA from the
nucleus was transported to dendrites.

The transport rate was found

to be 0.4 - 0.5 mm per day. This RNA transport could be blocked by
metabolic inhibitors (39).
The finding of polyribsomes In neuronal processes gave further
credence for the theory that translation does not de facto occu r at
the same sites for all mRNAs.

In 1982, Bruckenstein et al. found

polysomes selectively localized beneath synaptic junctions (40).

If

previous theory held true, there would be no rational explanation for
translational machinery to be found outside the cell body.

This

finding supported the idea that mRNAs may exist which are
transported to their final destination before they are translated.
Although the exact mechanism of mRNA localization is still
unknown, a model of how this may occur is presented in a review by
Wilhelm (41).

In this theory, mRNA associates with other

ribonucleoproteins to form an RNP particle.

The RNP particle

IS

actively translocated to its destination, and then anchors to the
cytoskeleton.

The evidence that mRNA transport is facilitated by

RNPs was first demonstrated in oligodendrocytes.

By visualizing

fluorescently labeled myelin basic protein (MBP) mRNA, Ainger et al.
(42) found the mRNA forming uniformly sized particles within
minutes after being injected into oligodendrocytes.

MBP mRNA, as

seen by in situ hybridization, displayed a granular pattern in the
cytoplasm.

These granular particles were seen to be in close

proximity to microtubules within the oligodendrocytes, suggesting
that the cytoskeleton serves some anchoring function.
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Several other studies have provided further evidence that
there is direct contact between RNPs and the cytoskeleton.

After

disruption of the cell cytoskeleton, Davis et al. found RNA still
bound to the cytoskeleton (39).

Bassell et al. reported that in

cultured cerebrocortical neurons poly A mRNA is associated with
microtubules (43).

In a study which compared differently localized

mRNAs in primary neuronal cells, Litman et al. found mRNAs that are
localized to the neuronal processes (tau and MAP2) are associated
with microtubules.

RNAs that encode proteins which are only found

in the neuronal cell body (tubulin), however, were not found to be
associated with microtubules (44).

These findings suggest that

microtubule association is necessary for transport of RNA to
neuronal processes.
It is believed that the microtubules and microfilaments found
attached to the RNPs serve as "tracks" for their localization.
Transport of these RNPs does not appear to be a random, diffusable
process.

Studying the progress of the fluorescently-Iabeled MBP

mRNA Ainger et al. found the motion of the RNA from the cell body of
oligodendrocytes through their long processes to the membrane
sheets to be unidirectional (42).

Davis' study also showed that the

transport of RNA in hippocampal neurons is a neatly orchestrated,
unidirectional process (39).
The RNPs, therefore, appear to ultimately control the final
location of the RNA.

A signal which lies in the transcript itself

appears to be responsible for the binding of the RNA to its "transport
vehicle" (the RNPs).

Wilhelm reviews a number of transcripts whose

localization signals have been identified by comparing the transport
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of the normal RNA with that of deletion mutants (41).

In all known

cases thus far, it appears that this signal is contained in the 3'
untranslated region of the transcript.

There are two alternative

polyadenylation sites for the cannabinoid receptor transcript.
alternative sites result in two different 3' UTRs (15).

These

It is

therefore possible that the two transcripts may differ in their
subcellular

localization.

The localization of the cannabinoid receptor and its RNA have
been studied in the brain.

Using a radiolabeled synthetic cannabinoid

Herkenham et al. (45) found that binding is greatest in the
cerebellum and the outflow nuclei of the basal ganglia.

The

molecular layer of the cerebellum contains the cannabinoid
receptors (45), yet the majority of cannabinoid receptor RNA
found in the granular layer (46).

IS

This mismatch between receptors

and RNA is explained by the fact that the neurons in the granular
layer project their axons to the molecular level.

Similarly in the

substantia nigra and globus pallidus, very high densities of
receptors are found but little to no receptor RNA is detected (45,
47).

It seems plausible, therefore, that preferential localization of

cannabinoid receptor mRNA to neuronal processes indeed occurs.
Where the localization signal resides on the RNA or the protein
itself has yet to be ascertained.
In order to answer the many question involving the expression
and regulation of the cannabinoid receptor gene, constructs must be
made which delete certain segments of the A and B transcripts.

Now

that both transcripts have been defined experiments can be under
way.
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